Taken together, the data suggest that neither the relative degree of resistance to taxanes (low or high), nor the underlying mechanism(s) of resistance to taxanes (whether PGP/MRP-mediated or not) affect the relative growth inhibition response of the PCa cells to the AKT or ErbB-small-molecule kinase inhibitors, thus making such inhibitors potentially attractive agents to use to target both wild-type and chemotherapy-resistant PCa. Here, PGP is linked to posterior cortical atrophy.